Literature DB >> 954096

Insulin receptors in normal and transformed fibroblasts: relationship to growth and transformation.

P Thomopoulos, J Roth, E Lovelace, I Pastan.   

Abstract

The insulin receptors in normal and transformed lines of mouse Balb/3t3 fibroblasts have been studied. In the normal fibroblasts, the binding of insulin was low in growing cells and increased 2-9 fold in confluent stationary cells. Insulin binding was increased whether growth arrest was due to contact inhibition of growth or serum starvation. When serum-starved cells were stimulated to grow by the addition of fresh serum, insulin binding declined. In cells transformed by simian virus 40, Kirsten, Moloney, and Harvey sarcoma viruses, methylcholanthrene, X rays, or spontaneously, the binding was low, in the same range as growing normal cells. In simian virus 40-transformed cells, insulin binding increased 4 fold as the cells reached higher densities in culture. No relationship to changes in cell size was found. The differences in binding were due to changes in the concentration of the receptors, without changes in their affinity for the hormone.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954096     DOI: 10.1016/0092-8674(76)90154-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  25 in total

1.  Quantitative determination of the lateral diffusion coefficients of the hormone-receptor complexes of insulin and epidermal growth factor on the plasma membrane of cultured fibroblasts.

Authors:  J Schlessinger; Y Shechter; P Cuatrecasas; M C Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

2.  Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells.

Authors:  J Schlessinger; Y Shechter; M C Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

3.  c-ras-Ha gene expression is regulated by insulin or insulinlike growth factor and by epidermal growth factor in murine fibroblasts.

Authors:  K H Lu; R A Levine; J Campisi
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

4.  Differential desensitization of functional adrenergic receptors in normal and malignant myeloid cells: relationship to receptor-mediated hormone cytotoxicity.

Authors:  R Simantov; L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

5.  Regulation of the transcript for a lysosomal protein: evidence for a gene program modified by platelet-derived growth factor.

Authors:  K K Frick; P J Doherty; M M Gottesman; C D Scher
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

6.  Alterations in insulin binding accompanying differentiation of 3T3-L1 preadipocytes.

Authors:  B C Reed; S H Kaufmann; J C Mackall; A K Student; M D Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

7.  Virus-induced decrease of insulin receptors in cultured human cells.

Authors:  F Shimizu; J J Hooks; C R Kahn; A L Notkins
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

8.  Insulin and serum increase the number of receptors for vasopressin in a kidney-derived line of cells grown in a defined medium.

Authors:  C Roy; A S Preston; J S Handler
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

9.  The number of receptors for beta-melanocyte stimulating hormone in Cloudman melanoma cells is increased by dibutyryl adenosine 3':5'-cyclic monophosphate or cholera toxin.

Authors:  A DiPasquale; J McGuire; J M Varga
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

10.  Sequential addition of platelet factor and plasma to BALB/c 3T3 fibroblast cultures stimulates somatomedin-C binding early in cell cycle.

Authors:  D R Clemmons; J J Van Wyk; W J Pledger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.